Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by KANTHARIA, B. K.
Right arrow Articles by COX, N. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KANTHARIA, B. K.
Right arrow Articles by COX, N. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 British Society for Rheumatology

research-article

THYMOPENTIN (TP-5) IN THE TREATMENT OF RHEUMATOID ARTHRITIS

B. K. KANTHARIA*, N. J. GOULDING*, N. D. HALL*, J. DAVIES*, P. J. MADDISON*,1, P. A. BACON{dagger}, M. FARR{dagger}, J. A. WOJTULEWSKI{ddagger}, K. M. ENGLEHART{ddagger}, S. P. LIYANAGE and N. L. COX,§

*Royal National Hospital for Rhematic Diseases, Bath and Pharmacology Group, University of Bath
{dagger}University of Birmingham Medical School Birmingham
{ddagger}District General Hospital Eastbourne
Hcathcrwood Hospital Ascot
§Royal Hampshire County Hospital Winchester

Correspondence to: 1Address correspondence to: Prof. P. J. Maddison, Consultant Rheumatologist, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1RL, UK.

A randomized control trial of TP-5 in rheumatoid arthritis is reported. In a multicentre study, 76 patients were treated with TP-5 50 mg or placebo three times a week for 3 weeks as a slow intravenous injection, and followed for 7 weeks. Clinical parameters such as the Ritchie index and sum score of swollen joints improved significantly on TP-5 compared to placebo. Laboratory parameters did not change but an increased skin test score to common recall antigens was observed. Toxicity was minimal. TP-5 is a potentially useful agent in the treatment of rheumatoid arthritis, although further studies are required to determine the optimal treatment regimen.

KEY WORDS: Thymopentin, Skin tests, T-cell subsets, Joint inflammation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Genome ResHome page
R Berger, L Theodor, J Shoham, E Gokkel, F Brok-Simoni, K B Avraham, N G Copeland, N A Jenkins, G Rechavi, and A J Simon
The characterization and localization of the mouse thymopoietin/lamina-associated polypeptide 2 gene and its alternatively spliced products.
Genome Res., May 1, 1996; 6(5): 361 - 370.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.